Literature DB >> 19579149

Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy.

Andrea Mariano1, Gianpaolo Scalia Tomba, Maria Elena Tosti, Enea Spada, Alfonso Mele.   

Abstract

Our objective was to estimate HCV clinical burden over time in Italy. A national age-specific HCV prevalence in 1995 was obtained from studies conducted in general population samples and intravenous drug users. Age profile of new HCV infections and trend of incidence since 1985 were derived from a database of reported acute HCV infections. These incidence and prevalence data were used to estimate HCV burden from 1950 to 2030 by mathematical modelling. Different rates of HCV related liver disease progression were tested to assess the robustness of estimates. It is estimated that HCV had a major spread in Italy in 1945-1969. HCV RNA-positive subjects peaked around 1970; their prevalence in 2005 was 3.2%, 58% of them being >65 y of age. The number of individuals with HCV related cirrhosis and that of HCV liver related deaths peaked in 1980-1985. In 2005, they were approximately 230,000 (range 150,000-240,000, according to lower or higher disease progression rates) and approximately 7,000 (range 2200-12,300), respectively: both will be halved by 2025. In conclusion, unlike other industrialized countries, the burden of clinically relevant HCV-positive cases in Italy is already on the decline and will further reduce in the future. This is due to differences in the age-specific prevalence, most of HCV-positive Italians currently being >65 y of age.

Entities:  

Mesh:

Year:  2009        PMID: 19579149     DOI: 10.1080/00365540903095358

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  12 in total

Review 1.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

2.  Hepatitis C Virus infections trends in Italy, 1996-2006.

Authors:  Giuseppe La Torre; Maria Rosaria Gualano; Leda Semyonov; Nicola Nicolotti; Walter Ricciardi; Antonio Boccia
Journal:  Hepat Mon       Date:  2011-11-30       Impact factor: 0.660

3.  Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience.

Authors:  Alessandra Mangia; Giovanni Cenderello; Alessandra Orlandini; Valeria Piazzolla; Antonio Picciotto; Massimo Zuin; Alessia Ciancio; Giuseppina Brancaccio; Paolo Forte; Vito Carretta; Anna Linda Zignego; Nicola Minerva; Gaetano Brindicci; Massimo Marignani; Gianluca Svegliati Baroni; Gaetano Bertino; Giuseppe Cuccorese; Leonardo Mottola; Maria Ripoli; Mario Pirisi
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 4.  Update on epidemiology of HCV in Italy: focus on the Calabria Region.

Authors:  Nadia Marascio; Maria Liberto; Giorgio Barreca; Emilia Zicca; Angela Quirino; Angelo Lamberti; Giovanna Bianco; Giovanni Matera; Lorenzo Surace; Giuseppina Berardelli; Lidia Surace; Vincenzo De Maria; Francesca Giancotti; Rosa Leone; Vilma Villella; Salvatore Nisticò; Annelisa Borelli; Vincenzina Caruso; Massimo Calderazzo; Gianfranco Griffo; Rosanna Masciari; Pasquale Minchella; Lucio Cosco; Carmelo Laganà; Angela Oliva; Giuseppe Foti; Maria Fiorillo; Giuseppa Bocchiaro; Pasquale Surace; Anna Ciccaglione; Massimo Ciccozzi; Francesco Cesario; Carlo Torti; Alfredo Focà
Journal:  BMC Infect Dis       Date:  2014-09-05       Impact factor: 3.090

5.  Mortality associated with hepatitis C and hepatitis B virus infection: A nationwide study on multiple causes of death data.

Authors:  Ugo Fedeli; Enrico Grande; Francesco Grippo; Luisa Frova
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

6.  High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55-85.

Authors:  Annarita Valeria Piazzolla; Giulia Paroni; Francesca Bazzocchi; Mauro Cassese; Antonio Cisternino; Luigi Ciuffreda; Franco Gorgoglione; Leonardo Gorgoglione; Vincenzo Palazzo; Natale Sciannamè; Marco Taurchini; Pasquale Vaira; Giovanna Cocomazzi; Maria Maddalena Squillante; Filippo Aucella; Nicola Cascavilla; Salvatore De Cosmo; Michelantonio Fania; Antonio Greco; Antonio Laborante; Maurizio Leone; Evaristo Maiello; Mauro Salvatori; Lazzaro Di Mauro; Alessandra Mangia
Journal:  Pathogens       Date:  2021-06-03

Review 7.  Molecular signature in HCV-positive lymphomas.

Authors:  Valli De Re; Laura Caggiari; Marica Garziera; Mariangela De Zorzi; Ombretta Repetto
Journal:  Clin Dev Immunol       Date:  2012-08-16

8.  HCV infected prisoners: should they be still considered a difficult to treat population?

Authors:  Fabio Iacomi; Giuseppina Iannicelli; Andrea Franceschini; Paolo Migliorisi; Silvia Rosati; Pierluca Piselli; Paola Scognamiglio; Gabriella De Carli; Sonia Marcellini; Fabrizio Palmieri
Journal:  BMC Infect Dis       Date:  2013-08-14       Impact factor: 3.090

9.  Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association.

Authors:  V D Hope; I Eramova; D Capurro; M C Donoghoe
Journal:  Epidemiol Infect       Date:  2013-05-29       Impact factor: 4.434

10.  Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.

Authors:  Francesco Saverio Mennini; Andrea Marcellusi; Massimo Andreoni; Antonio Gasbarrini; Salvatore Salomone; Antonio Craxì
Journal:  Clinicoecon Outcomes Res       Date:  2014-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.